If your organization is already selling medical devices in Europe or the United States, Canada's regulatory requirements may seem familiar. Yet there is one significant difference: for most licensed medical devices, ISO 13485 certification alone is not enough.
Loading...
How to Sell Medical Devices in Canada: A Guide to Health Canada Requirements and MDSAP
Loading...
Loading...
How Can I Access the Canadian Medical Device Market?
Canada is one of the world’s most established healthcare markets, making it an attractive destination for medical device manufacturers seeking international growth.
However, entering the Canadian market requires more than implementing a quality management system. Manufacturers must understand Health Canada’s regulatory framework, correctly classify their devices, complete the appropriate licensing process, and—for most licensed medical devices—demonstrate compliance through the Medical Device Single Audit Program (MDSAP).
For organizations already selling medical devices in the United States or European Union, many elements of the Canadian regulatory framework may appear familiar. There is, however, one important distinction: for most licensed medical devices, ISO 13485 certification alone is not sufficient.
This guide provides an overview of Canada’s medical device regulatory framework, device classification, market authorization requirements, the role of MDSAP, and several common mistakes manufacturers should avoid when entering the Canadian market.
Canada’s Medical Device Market: Why It Matters
Canada is a mature, highly regulated healthcare market with a transparent regulatory framework overseen by Health Canada.
For manufacturers pursuing international expansion, Canada offers several advantages:
- Clear and established regulatory requirements
- A strong focus on product quality and patient safety
- Participation in internationally recognized regulatory initiatives such as MDSAP
- A healthcare system that places significant value on compliant, high-quality medical technologies
Canada’s participation in MDSAP can also benefit manufacturers pursuing access to multiple international markets. Rather than managing entirely separate quality system audits for each participating jurisdiction, manufacturers can undergo a single MDSAP audit that addresses applicable requirements across participating regulatory authorities.
According to the 2025 MDSAP Regulatory Authority Council Report, the program includes more than 7,600 participating manufacturers across 84 jurisdictions.
Loading...
Dr. Yuan Li, Director of Medical Device Business at DQS
Canada has developed one of the world’s most transparent regulatory pathways for medical devices. Manufacturers that prepare early for MDSAP often find their transition into the Canadian market significantly more predictable.
Loading...
Understanding Medical Device Regulation in Canada
Medical devices in Canada are regulated by Health Canada under the Food and Drugs Act and the Medical Devices Regulations (SOR/98-282).
Health Canada evaluates medical devices for safety, effectiveness, and quality before authorizing applicable products for sale. The agency also oversees important post-market activities, including:
- Post-market surveillance
- Medical device incident reporting
- Recalls and corrective actions
- Licensing
- Ongoing regulatory compliance
Understanding these requirements early in the market-entry process can help manufacturers avoid unnecessary delays and identify regulatory or quality system gaps before commercialization.
Medical Device Classification in Canada
Canada classifies medical devices according to four risk-based categories:
Class I – Lowest risk
Class II – Low to moderate risk
Class III – Moderate to high risk
Class IV – Highest risk
A device’s classification determines its regulatory pathway, licensing requirements, and the level of documentation and regulatory review required.
Correct classification is therefore one of the first—and most important—steps when planning Canadian market entry.
Loading...
Early planning is particularly important for manufacturers that do not already participate in MDSAP, as certification should be incorporated into the overall market-entry timeline.
Medical Device Submission and Licensing Process in Canada
Although specific requirements vary according to device classification, a typical market-entry process includes the following steps:
1. Determine the appropriate device classification.
2. Establish and maintain a compliant quality management system.
3. Obtain MDSAP certification for Class II, III, and IV devices.
4. Submit the applicable Medical Device Licence application to Health Canada.
5. Maintain ongoing regulatory and post-market compliance after authorization.
Why MDSAP Is Different
One of the most important distinctions between Canada and many other major medical device markets is the role of MDSAP.
For manufacturers of Class II, III, and IV medical devices, Health Canada requires demonstration of ISO 13485 compliance through an MDSAP-recognized Auditing Organization before applicable devices can be licensed.
MDSAP enables a single audit approach recognized by participating regulatory authorities in:
- Australia
- Brazil
- Canada
- Japan
- United States
The audit assesses the manufacturer’s quality management system against ISO 13485 together with applicable country-specific regulatory requirements.
Loading...
Manufacturers sometimes discover late in their market-entry planning that ISO 13485 certification alone does not satisfy Health Canada’s licensing requirements for Class II, III, and IV devices.
For this reason, companies considering Canadian market entry should evaluate their MDSAP readiness early rather than treating certification as a final step before submission.
Canada vs. United States vs. European Union: Medical Device Regulatory Comparison
| Topic | Canada | United States | European Union |
|---|---|---|---|
| Primary regulator | Health Canada | U.S. FDA | European Commission, National Competent Authorities, and Notified Bodies |
| Main regulatory framework | Medical Devices Regulations (SOR/98-282) | Federal Food, Drug, and Cosmetic Act and applicable 21 CFR requirements | MDR (EU) 2017/745 |
| Device classification | Class I, II, III, IV | Class I, II, III | Class I, IIa, IIb, III |
| Quality Management System | MDSAP-certified ISO 13485:2016 QMS required for Class II–IV devices | QMSR incorporating ISO 13485:2016 plus applicable FDA regulatory requirements | MDR Article 10(9) QMS requirements, commonly implemented using ISO 13485:2016 together with MDR-specific requirements |
| Role of MDSAP | Required for Class II–IV licensing | Voluntary; FDA may use MDSAP audit reports in place of certain routine inspections | Does not replace MDR conformity assessment; MDSAP audit results may provide useful evidence during QMS assessment and surveillance |
| Market authorization | Medical Device Licence for Class II–IV devices | 510(k), De Novo, PMA, or exemption, depending on the device | CE Mark following applicable conformity assessment |
| Third-party assessment | MDSAP-recognized Auditing Organization | FDA inspections and/or MDSAP-recognized Auditing Organization audits | MDR-designated Notified Body for applicable device classes |
| Post-market obligations | Complaint handling, recalls, incident reporting, and ongoing QMS compliance | Medical Device Reporting, corrections and removals, inspections, and other applicable requirements | Vigilance, PMS, PMCF, periodic reporting, and Notified Body surveillance |
| Key distinction | ISO 13485 alone is not sufficient for most licensed devices; MDSAP certification is required for Class II–IV | MDSAP is not generally mandatory for market authorization | CE Marking or EU market access does not automatically provide access to the Canadian market |
Manufacturers already operating in the United States or European Union may therefore be able to leverage elements of their existing quality and regulatory systems when entering Canada—but they should not assume that existing FDA compliance, CE Marking, or ISO 13485 certification automatically satisfies Canadian requirements.
Loading...
FDA Medical device cybersecurity mandate
Join Dr. Yuan Li on September 10, 2026 to discuss how to close the gap between regulatory requirements and real-world implementation, in partnership with Omnex.
Loading...
For manufacturers pursuing international expansion, MDSAP can offer significant advantages by creating a more coordinated approach to quality system oversight.
Benefits of MDSAP
Key benefits include:
1. One Audit Supporting Multiple Regulatory Authorities
MDSAP allows manufacturers to undergo a single audit that addresses the applicable quality management system requirements of multiple participating regulatory authorities.
This can reduce duplication compared with managing separate quality system audit programs for each participating market.
2. Support for International Expansion
Because MDSAP is recognized across several major medical device markets, participation can support a broader international regulatory strategy.
For manufacturers already targeting markets such as Australia, Brazil, Canada, Japan, or the United States, an MDSAP-certified quality management system can provide a stronger foundation for managing multiple regulatory requirements.
3. Demonstration of a Mature Quality Management System
MDSAP audits go beyond evaluating ISO 13485 alone. They also assess applicable country-specific regulatory requirements.
Successful certification can therefore demonstrate that a manufacturer has established a mature and well-controlled quality management system capable of meeting multiple regulatory expectations.
This can strengthen confidence among regulators, customers, and other business partners.
Common Mistakes When Entering the Canadian Medical Device Market
Manufacturers entering regulated international markets can encounter avoidable delays when regulatory planning begins too late.
Several mistakes are particularly common.
1. Assuming ISO 13485 Certification Alone Is Sufficient
ISO 13485 provides the foundation for a medical device quality management system, but manufacturers of Class II, III, and IV devices must demonstrate compliance through an MDSAP-recognized Auditing Organization to meet Health Canada licensing requirements.
This distinction should be understood at the beginning of the Canadian market-entry process.
2. Incorrectly Classifying the Device
Incorrect device classification can lead to inappropriate regulatory strategies, incomplete submissions, delays, or additional regulatory scrutiny.
Manufacturers should determine the applicable Canadian classification before developing the submission strategy.
3. Delaying MDSAP Preparation
Waiting until shortly before commercialization to begin MDSAP preparation can create unnecessary risk.
Manufacturers may discover quality system gaps that require time to resolve before certification can be completed.
MDSAP planning should therefore be incorporated into the overall commercialization timeline.
4. Underestimating Post-Market Obligations
Regulatory compliance does not end when a medical device receives market authorization.
Manufacturers must continue to maintain appropriate processes for:
· Post-market surveillance
· Complaint handling
· Medical device incident reporting
· Recalls and corrective actions
· Corrective and preventive action (CAPA)
· Ongoing quality management system compliance
A sustainable Canadian regulatory strategy should consider the entire device lifecycle, not simply the initial licence application.
Loading...
Preparing for Successful Canadian Market Entry
The most effective Canadian market-entry strategies begin well before the licence application is submitted.
Manufacturers should establish their device classification, regulatory pathway, quality system requirements, and MDSAP strategy early in the commercialization process.
For organizations already operating internationally, Canada can represent a logical next market—but existing ISO 13485 certification, FDA compliance, or CE Marking should not be assumed to satisfy Canadian requirements automatically.
Early preparation can reduce regulatory uncertainty, identify quality system gaps before they become critical, and make the path to commercialization more predictable.
Regulatory success begins long before the application is submitted.
Explore MDSAP for your company
Avoid unnecessary delays by preparing your Canadian regulatory and MDSAP strategy early.
Author
Yuan Li, PhD
Dr. Yuan Li holds a doctorate in Mechanical Engineering and has published 13 studies on spinal pathologies and implant innovation. He built his career in Regulatory Affairs, guiding 510(k) and CE certifications across the U.S., EU, and APAC regions. Since joining the notified body sector in 2015, he has advanced from orthopedic product reviewer to management, now overseeing North American operations with a focus on market growth and compliance.
Loading...
